---
title: "Tempus AI lifts 2026 revenue outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285257942.md"
datetime: "2026-05-05T20:10:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285257942.md)
  - [en](https://longbridge.com/en/news/285257942.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285257942.md)
---

# Tempus AI lifts 2026 revenue outlook

)

Overview

-   U.S. AI precision medicine firm’s Q1 revenue grew 36% yr/yr, slightly beating analyst expectations
-   Adjusted EBITDA loss for Q1 narrowed and beat analyst estimates
-   Company raised full-year 2026 revenue guidance to $1.59-$1.60 bln

Outlook

-   Tempus AI raises 2026 revenue guidance to $1.59-$1.60 bln
-   Company continues to expect 2026 Adjusted EBITDA of ~$65 mln
-   Tempus AI says strong demand for AI-driven diagnostics and data modeling expected to continue

Result Drivers

-   ONCOLOGY & HEREDITARY VOLUME - Diagnostics revenue grew 34.7% yr/yr, driven by 28% Oncology volume growth and 54% Hereditary volume growth (7% after adjusting for Ambry acquisition timing)
-   MRD TESTING - MRD test volume rose ~500% yr/yr to ~6,500 tests, supporting Diagnostics segment growth
-   DATA & APPLICATIONS MOMENTUM - Data and Applications revenue grew 40.5% yr/yr, with Insights (data licensing and modeling) up 44.1% Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Slight $348.12 $345.46

Revenue Beat\* mln mln (15

Analysts

)

Q1 Net -$125.92

Income mln

Q1 Beat -$2.83 -$4.74

Adjusted mln mln (9

EBITDA Analysts

)

### Q1 -$84.71

Income mln

from

Operatio

ns

\*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 11 “strong buy” or “buy”, 7 “hold” and 1 “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Tempus AI Inc is $80.00, about 43.3% above its May 4 closing price of $55.81 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [TRI.US](https://longbridge.com/en/quote/TRI.US.md)
- [LSEG.UK](https://longbridge.com/en/quote/LSEG.UK.md)
- [LNSTY.US](https://longbridge.com/en/quote/LNSTY.US.md)
- [LSEGY.US](https://longbridge.com/en/quote/LSEGY.US.md)

## Related News & Research

- [BUZZ-Tempus AI rises after boosted $400 mln convertible bond offering](https://longbridge.com/en/news/285720904.md)
- [Bogart Wealth LLC Raises Stock Holdings in Tempus AI, Inc. $TEM](https://longbridge.com/en/news/284529452.md)
- [TG Therapeutics Q1 revenue rises, lifts 2026 outlook](https://longbridge.com/en/news/285364463.md)
- [Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients | CAI Stock News](https://longbridge.com/en/news/284572256.md)
- [Cathie Wood Dumps Another $3 Million In AMD Stock As Ark Invest Trims For Third Day Running, This Is the AI Stock She Is Buying Instead](https://longbridge.com/en/news/285658201.md)